BY MARKETWIRE
-
GN cuts debt further as dividend remains on hold
More financial debt decrease is needed prior to the Danish hearing team returns to investor payments.
-
Novo Nordisk to promote Wegovy at Super Bowl as part of intensified marketing focus
With reduced rates in the United States, Novo Nordisk should rather bring in even more consumers, which is why the Danish firm is spending greatly in advertising.
-
Coloplast stock may suffer from weak start to the year, says analyst
On the whole, Coloplast’s first-quarter outcomes are somewhat unsatisfactory, according to an elderly expert at Sydbank.
-
GN takes a beating during teleconference with analysts
GN’s target price lowered by DNB Carnegie after financial results.
-
Hims and Hers turns negative after threat from Novo Nordisk
After Novo Nordisk provided a caution on Thursday regarding lawsuits versus Hims and Hers’ duplicate tablet, the supply has actually gone down considerably.
-
Doustdar doubts effect of copy pill: “Waste of 49 dollars”
Mike Doustdar questions Hims and Hers’ duplicate of the fat burning tablet Wegovy, which is currently on the marketplace.
-
Eli Lilly’s Zepbound sales outperform expectations
Unlike its rival Novo Nordisk, Eli Lilly anticipates substantial development in sales in 2026.
-
Growth forecast will be crucial in GN’s annual report
Janne Vincent Kjær, an expert at Jyske Financial institution, sees the opportunity that GN will certainly release a brand-new item system for listening device in the 2nd fifty perc…
-
Novo Nordisk CFO: It’s a shame that we disappoint with our expectations
Novo CFO Karsten Munk Knudsen is let down to allow investors down with the revealed assumptions for the year.
-
Novo Nordisk with significant decline in the fourth quarter, but Wegovy slightly exceeds estimates
Novo Nordisk finished the year on a slump in the 4th quarter.
